New Data Supports DNA Vaccine Delivery via Vaxxas’ HD-MAP Technology Vaxxas, a clinical-stage biotechnology company specializing in a novel vaccination platform, announced today the publication of data validating the effectiveness…
Cadrenal Therapeutics Partners with Abbott for Tecarfarin Pivotal Study in HeartMate 3™ LVAD Patients Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company specializing in cardiovascular therapeutics, has announced the signing…
FDA Grants Orphan and Pediatric Designations to NEU-001 for Hirschsprung’s Disease Neurenati Therapeutics Inc., a biotechnology company dedicated to pediatric rare diseases, is excited to announce that the U.S. Food…
Centauri Therapeutics Selects First Clinical Candidate for Gram-Negative Infection Treatment Centauri Therapeutics Limited, an immunotherapy company leveraging its unique Alphamer® platform technology, has announced the selection of its first clinical…
Osivax Secures Funding to Advance Influenza Vaccine Development Osivax, a biopharmaceutical company focused on developing vaccines for broad-spectrum protection against rapidly mutating respiratory viruses, has announced the successful first close…
Actio Biosciences Doses First Participant in Phase 1 Trial of ABS-0871 for CMT2C Actio Biosciences, a clinical-stage biotechnology company focused on using its “one to many” paradigm in genetics and…
SOTIO Reveals Promising Preclinical Data on SOT109 for Colorectal Cancer SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled groundbreaking preclinical data for SOT109, a novel antibody-drug…
KalVista Presents Latest Sebetralstat Findings at AAAAI 2025 KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data on sebetralstat at the 2025 American Academy of Allergy, Asthma…
Gensaic Partners with Novo Nordisk to Develop Next-Gen Precision Therapies Gensaic, Inc., a biotechnology firm specializing in AI-driven protein design and biological insights to discover ligands for tissue-selective intracellular delivery,…
QIAGEN Takes Legal Action to Protect IP in QuantiFERON and Latent TB Testing QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a lawsuit against bioMérieux SA (EPA: BIM)…
BostonGene to Present AI-Powered Platform at 22nd Annual Japanese Society of Medical Oncology Meeting BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced its participation in the…
BeiGene Reports Q4 & Full Year 2024 Financial Results and Update BeiGene, Inc. (NASDAQ: ONC, HKEX: 06160, SSE: 688235), soon to be rebranded as BeOne Medicines Ltd., a global leader…